Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand
ConclusionAmong three COVID-19-vaccinated immunocompromised patient populations, this study concluded that Evusheld was cost-effective for dialysis patients with inadequate immune response to the COVID-19 vaccine.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Autoimmune Disease | Coronavirus | Covid Vaccine | COVID-19 | Dialysis | Economics | Health Management | Study | Thailand Health | Transplants | Vaccines